14 reports

  • EUROPE LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2016-2024) ($MN)
  • Historical Data and trends of Liquid Biopsy Global Market

TABLE ## TABLE ## HEART TRANSPLANTATION DIAGNOSTIS GLOBAL TOTAL ADDRESSABLE MARKET (TAM) (2017)($MN) According to IQ##I analysis, the Total Addressable Market (TAM) for heart transplantation globally was estimated to be $##. ## million.

  • Genetic Testing
  • World
  • Market Size
  • Biocept, Inc.
  • Guardant Health, Inc.
  • DIAGNOSTIC TEST - HEART TRANSPLANTATION PRODUCT OVERVIEW

WE ARE ALSO EXCITED ABOUT THE DEMONSTRATED VALUE OF OUR IL-## PLATFORM IN CARDIAC DISEASE.

  • Clinical Trial
  • Genetic Testing
  • Hospital
  • Mental Health
  • AutoGenomics, Inc.

WE ARE ALSO EXCITED ABOUT THE DEMONSTRATED VALUE OF OUR IL-## PLATFORM IN CARDIAC DISEASE.

  • Genetic Testing
  • Genomics
  • Hospital
  • Pharmaceutical
  • Thermo Fisher Scientific, Inc.
  • DIAGNOSTIC TEST - HEART TRANSPLANTATION - PRODUCT STATUS

We are also excited about the demonstrated value of our IL-## platform in cardiac disease.

  • Clinical Trial
  • Genetic Testing
  • Prostate Cancer
  • United States
  • AutoGenomics, Inc.
  • 2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES
  • APPLICATION

START-UP IS DEVELOPING CELL-FREE DNA TECHNOLOGY FOR HEART TRANSPLANT PATIENTS.

  • Genetic Testing
  • Biocept, Inc.
  • CareDx, Inc.
  • Illumina, Inc.
  • Natera, Inc.

Rat Heterotopic Heart Transplantation Model to Investigate Unloading-Induced Myocardial Remodeling.

  • Genetic Testing
  • Charles River Laboratories International, Inc.
  • genOway SA
  • Horizon Discovery
  • Taconic Biosciences, Inc.

Both companies have well-established core products in transplantation: CareDx' s AlloMap® for acute cellular rejection in heart transplant patients, and Allenex' s Olerup SSP® for HLA matching of donors and recipients.

  • Biotech Diagnostics
  • Genetic Testing
  • United States
  • Market Size
  • Roche Group

Both companies have well-established core products in transplantation: CareDx' s AlloMap® for acute cellular rejection in heart transplant patients, and Allenex' s Olerup SSP® for HLA matching of donors and recipients.

  • Genetic Testing
  • Medical Biotechnology
  • United States
  • Market Size
  • Roche Group

Both companies have well-established core products in transplantation: CareDx' s AlloMap® for acute cellular rejection in heart transplant patients, and Allenex' s Olerup SSP® for HLA matching of donors and recipients.

  • Genetic Testing
  • Medical Biotechnology
  • United States
  • Market Size
  • Roche Group

Both companies have well-established core products in transplantation: CareDx' s AlloMap® for acute cellular rejection in heart transplant patients, and Allenex' s Olerup SSP® for HLA matching of donors and recipients.

  • Genetic Testing
  • Medical Biotechnology
  • United States
  • Market Size
  • Roche Group

HE WAS ONE OF THE PIONEERS IN CARDIAC CELL THERAPY IN EUROPE AND STARTED WITH THE FIRST TRIALS IN 2001.

  • Cell Therapy
  • Genetic Testing
  • Hospital
  • Regenerative Medicine
  • United States

Transplantation: Biopsies of transplanted organs are performed in order to determine that they are not being rejected or that the disease that necessitated transplant has not recurred.

  • Genetic Testing
  • United States
  • Market Size
  • Illumina, Inc.
  • Trovagene, Inc.

Transplantation: Biopsies of transplanted organs are performed in order to determine that they are not being rejected or that the disease that necessitated transplant has not recurred.

  • Genetic Testing
  • United States
  • Market Size
  • Illumina, Inc.
  • Trovagene, Inc.

Trastuzumab was approved for patients with HER##-positive tumors in 1998 provided below: CANCER and further research in 2005 showed that it reduced recurrence by ##% in combination with chemotherapy Prior to the development of a gene expression profiling test to identify heart

  • Genetic Testing
  • Cargill Inc.
  • Genentech, Inc.
  • Pfizer Inc.
  • Roche Group